Endoscopic Mucosal Resection in Barrett s Esophagus

Location:

Rochester, Minn.

Trial status:

Open for Enrollment

Why is this study being done?

Barrett's esophagus (BE) is a complication of gastroesophageal reflux disease in which the normal squamous lining of the esophagus is replaced by specialized columnar epithelium.1 Approximately 5%-10% of patients diagnosed with BE are thought to be at risk of developing esophageal adenocarcinoma.2 Patients with high-grade dysplasia (HGD) on biopsy are at the greatest cancer risk³. EMR is being performed clinically in our Barrett's Esophagus Unit on a regular basis during endoscopy for patients with Barrett's Esophagus and/or early esophageal adenocarcinoma. There are two predominant endoscopic mucosal resection (EMR) techniques exist using FDA approved devices - the EMR cap method using a transparent cap/snare combination and the endoscopic variceal ligation method using a band ligator/snare combination to resect tissue.

Who is eligible to participate?

Inclusion Criteria: - Barrett's Esophagus Early Esophageal Adenocarcinoma History of Endoscopic Mucosal Resection Exclusion Criteria: - NA

Last updated:

1/17/2014

NCT ID:

NCT00586872

IRB Number:

07-007063